354 related articles for article (PubMed ID: 11520145)
1. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
Eisenkop SM; Spirtos NM
Gynecol Oncol; 2001 Sep; 82(3):489-97. PubMed ID: 11520145
[TBL] [Abstract][Full Text] [Related]
2. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
[TBL] [Abstract][Full Text] [Related]
3. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.
Dewdney SB; Rimel BJ; Reinhart AJ; Kizer NT; Brooks RA; Massad LS; Zighelboim I
Gynecol Oncol; 2010 Oct; 119(1):18-21. PubMed ID: 20673970
[TBL] [Abstract][Full Text] [Related]
4. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary.
Eisenkop SM; Spirtos NM; Lin WC
Gynecol Oncol; 2006 Oct; 103(1):329-35. PubMed ID: 16876853
[TBL] [Abstract][Full Text] [Related]
5. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
6. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
7. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
Bristow RE; Montz FJ
Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
[TBL] [Abstract][Full Text] [Related]
9. Organisation and quality of primary surgical intervention for ovarian cancer in Denmark.
Marx C; Bendixen A; Høgdall C; Ottosen C; Kehlet H; Ottesen B
Acta Obstet Gynecol Scand; 2007; 86(12):1496-502. PubMed ID: 17851818
[TBL] [Abstract][Full Text] [Related]
10. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
Li YF; Li MD; Liu FY; Liu JH; Li JD
Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
[TBL] [Abstract][Full Text] [Related]
11. Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training.
Frumovitz M; Ramirez PT; Greer M; Gregurich MA; Wolf J; Bodurka DC; Levenback C
Gynecol Oncol; 2004 Sep; 94(3):746-53. PubMed ID: 15350368
[TBL] [Abstract][Full Text] [Related]
12. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
13. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
14. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Shih KK; Chi DS; Barakat RR; Leitao MM
Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
[TBL] [Abstract][Full Text] [Related]
15. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
16. [Up-date on cytoreductive surgery in the management of advanced ovarian cancer].
Angioli R; Palaia I; Damiani P; Montera R; Benedetti Panici P
Minerva Ginecol; 2006 Dec; 58(6):459-70. PubMed ID: 17108876
[TBL] [Abstract][Full Text] [Related]
17. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN
Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer: patterns of surgical care across the United States.
Goff BA; Matthews BJ; Wynn M; Muntz HG; Lishner DM; Baldwin LM
Gynecol Oncol; 2006 Nov; 103(2):383-90. PubMed ID: 17005244
[TBL] [Abstract][Full Text] [Related]
20. Tertiary cytoreduction in patients with recurrent ovarian carcinoma.
Leitao MM; Kardos S; Barakat RR; Chi DS
Gynecol Oncol; 2004 Oct; 95(1):181-8. PubMed ID: 15385129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
